Φορτώνει......
Phase II Study of High-Dose [(131)I]Metaiodobenzylguanidine Therapy for Patients With Metastatic Pheochromocytoma and Paraganglioma
PURPOSE: To evaluate the safety and efficacy of high-dose [(131)I]metaiodobenzylguanidine ([(131)I]MIBG) in the treatment of malignant pheochromocytoma (PHEO) and paraganglioma (PGL). METHODS: Fifty patients with metastatic PHEO or PGL, age 10 to 64 years, were treated with [(131)I]MIBG doses rangin...
Αποθηκεύτηκε σε:
Κύριοι συγγραφείς: | , , , , , , , , , , |
---|---|
Μορφή: | Artigo |
Γλώσσα: | Inglês |
Έκδοση: |
American Society of Clinical Oncology
2009
|
Θέματα: | |
Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2734428/ https://ncbi.nlm.nih.gov/pubmed/19636009 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2008.21.3496 |
Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|